Largest biotech companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 20 biotech companies in the United States ranked by net assets, at NOK 221.8B, ahead of Biogen (NOK 178.3B) and Amgen (NOK 84.6B). Figures as of 20 Nov 2026, 07:57 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- Gilead SciencesNOK 221.8B
- Median
- NOK 15.7B
- Combined market value
- NOK 7.18T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | NOK 221.8B | NOK 2.02T | NOK 1,626.61 | 1.45% down | 35% up | ||
| 2 | BiogenBIIB · Health Care | NOK 178.3B | NOK 356.8B | NOK 2,413.88 | 1.70% down | 49% up | ||
| 3 | AmgenAMGN · Health Care | NOK 84.6B | NOK 2.32T | NOK 4,286.25 | 1.14% down | 32% up | ||
| 4 | ModernaMRNA · Health Care | NOK 84.5B | NOK 787.8B | NOK 1,946.99 | 1.29% up | 780% up | ||
| 5 | Neurocrine BiosciencesNBIX · Health Care | NOK 31.8B | NOK 154.8B | NOK 1,529.52 | 3.85% down | 17% up | ||
| 6 | VaxcytePCVX · Health Care | NOK 26.2B | NOK 90.2B | NOK 570.04 | 0.27% down | 23% up | ||
| 7 | ExelixisEXEL · Health Care | NOK 21.1B | NOK 156.9B | NOK 643.01 | 3.60% down | 63% up | ||
| 8 | Bio-TechneTECH · Health Care | NOK 20.6B | NOK 111.6B | NOK 710.11 | 0.07% down | 24% up | ||
| 9 | RepligenRGEN · Health Care | NOK 20.6B | NOK 106.3B | NOK 1,663.34 | 1.38% down | 12% up | ||
| 10 | Revolution MedicinesRVMD · Health Care | NOK 15.9B | NOK 336.8B | NOK 1,557.26 | 0.24% down | 129% up | ||
| 11 | Kymera TherapeuticsKYMR · Health Care | NOK 15.4B | NOK 99.6B | NOK 1,166.16 | 1.44% down | 87% up | ||
| 12 | Krystal BiotechKRYS · Health Care | NOK 11.9B | NOK 91.4B | NOK 3,084.83 | 0.15% up | 54% up | ||
| 13 | ImmunovantIMVT · Health Care | NOK 8.3B | NOK 65.7B | NOK 317.64 | 1.96% down | 46% up | ||
| 14 | CG OncologyCGON · Health Care | NOK 7.4B | NOK 71.5B | NOK 799.97 | 2.38% up | 97% up | ||
| 15 | Twist BioscienceTWST · Health Care | NOK 4.6B | NOK 74.3B | NOK 1,090.27 | 4.07% down | 346% up | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | NOK 2.4B | NOK 60B | NOK 492.00 | 4.94% up | 26% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | NOK 2.1B | NOK 44.4B | NOK 273.98 | 1.44% down | 74% up | ||
| 18 | Kodiak SciencesKOD · Health Care | NOK 1.5B | NOK 62.5B | NOK 956.25 | 0.09% up | 399% up | ||
| 19 | Halozyme TherapeuticsHALO · Health Care | NOK 476.8M | NOK 103.6B | NOK 908.78 | 2.88% down | 39% up | ||
| 20 | ImmunityBioIBRX · Health Care | -NOK 4.9B | NOK 68.3B | NOK 64.17 | 1.94% down | 232% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.7677 NOK).
Questions and answers
Which biotech companies in the United States rank first by net assets?
Gilead Sciences (NOK 221.8B), Biogen (NOK 178.3B) and Amgen (NOK 84.6B) are the top three of the 20 biotech companies in the United States ranked by net assets as of 20 Nov 2026, 07:57 UTC.
How many biotech companies in the United States are in this ranking?
20 are ranked by net assets.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by net assets have a combined market value of NOK 7.18T as of 20 Nov 2026, 07:57 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies in the United States by net assets”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.